INT13451

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 23
Total Number 23
Disease Relevance 9.33
Pain Relevance 3.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
Anatomy Link Frequency
fibroblasts 4
CD86 1
plasma 1
lymphocytes 1
cleavage 1
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 76 99.52 Very High Very High Very High
cytokine 200 99.24 Very High Very High Very High
Central nervous system 10 97.64 Very High Very High Very High
Neuropeptide 34 96.84 Very High Very High Very High
chemokine 221 94.84 High High
Inflammation 157 91.16 High High
substance P 19 90.04 High High
rheumatoid arthritis 167 84.32 Quite High
Calcitonin gene-related peptide 9 83.68 Quite High
calcitonin gene related peptide 3 83.44 Quite High
Disease Link Frequency Relevance Heat
Asthma 66 99.84 Very High Very High Very High
Diabetes Mellitus 415 98.80 Very High Very High Very High
Renal Cancer 117 98.76 Very High Very High Very High
Myocardial Infarction 11 97.80 Very High Very High Very High
Injury 3 94.88 High High
Coronary Artery Disease 6 94.56 High High
INFLAMMATION 156 91.16 High High
Increased Venous Pressure Under Development 10 90.96 High High
Cancer 227 90.16 High High
Neurogenic Inflammation 6 89.44 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As GIP and GLP-1 together are responsible for the incretin effect in healthy people, the incretin defect in T2DM could theoretically arise because of impaired secretion, accelerated metabolism, defective function of the incretin hormones or their associated receptors, increased activity of DPP-4 (Mannucci et al 2005) as well as through additional mechanisms, eg, action of neuropeptides (Nauck and El-Ouaghlidi 2005).
Positive_regulation (increased) of DPP-4 associated with diabetes mellitus and neuropeptide
1) Confidence 0.68 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.34 Pain Relevance 0.09
The resulting supernatants were used to measure soluble DPP IV activity, which is a truncated form of membrane-bound DPP IV/CD26 lacking some residues in the N-terminal aminoacids [16].
Positive_regulation (form) of DPP IV
2) Confidence 0.50 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.26 Pain Relevance 0
The resulting supernatants were used to measure soluble DPP IV activity, which is a truncated form of membrane-bound DPP IV/CD26 lacking some residues in the N-terminal aminoacids [16].
Positive_regulation (form) of CD26
3) Confidence 0.50 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.26 Pain Relevance 0
Quantitative DPP IV and NEP expression profile in renal tumors
Positive_regulation (Quantitative) of DPP IV associated with renal cancer
4) Confidence 0.50 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.42 Pain Relevance 0
These new treatments include glucose dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1) (“incretin”) mimetics as well as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Positive_regulation (dependent) of DPP-4
5) Confidence 0.49 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.76 Pain Relevance 0.05
Both GLP-1 and GIP are inactivated by DPP-4 resulting in a short half life, which is 1 to 2 min for GLP-1 and 5 to 7 min for GIP (Deacon 2005).
Positive_regulation (resulting) of DPP-4
6) Confidence 0.46 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.32 Pain Relevance 0
As a result of DPP-4 activity, intact, biologically active GLP-1 represents only 10% to 20% of total plasma GLP-1 (Deacon et al 1995).
Positive_regulation (result) of DPP-4 in plasma
7) Confidence 0.46 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.30 Pain Relevance 0
Activation of CD26 may increase CD86 expression on CD14 positive monocytes and other antigen presenting cells [44].
Positive_regulation (Activation) of CD26 in CD86
8) Confidence 0.44 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.45 Pain Relevance 0.13
A soluble form of DPP IV (sCD26) is elevated in asthma.
Positive_regulation (elevated) of DPP IV associated with asthma
9) Confidence 0.44 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.42 Pain Relevance 0.19
Intranasal steroid treatment increases NEP, and potentially DPP IV, expression.
Positive_regulation (increases) of DPP IV
10) Confidence 0.41 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.55 Pain Relevance 0.48
Biological fluids contain relatively high levels of sCD26, which is presumably shed by proteolytic cleavage from any cell expressing transmembrane CD26 [20].
Positive_regulation (levels) of sCD26 in cleavage
11) Confidence 0.40 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2912863 Disease Relevance 0.57 Pain Relevance 0
RESULTS: Significant differences were seen in lymphocyte phenotype in the methadone-treated group, with elevations in the T-cell helper subset CD4+CD26+; in CD8 and CD8+I2+ cells, suppressor/cytotoxic T lymphocytes, and activated suppressor/cytotoxic T cells; and in CD2+CD26+ cells and activated total T lymphocytes.
Positive_regulation (elevations) of CD26 in cytotoxic T lymphocytes
12) Confidence 0.39 Published 1991 Journal Am. J. Med. Section Body Doc Link 1671730 Disease Relevance 0.14 Pain Relevance 0
GLP-1 is degraded rapidly by the ubiquitous enzyme dipeptidyl-peptidase IV (DPP-4).
Positive_regulation (enzyme) of dipeptidyl-peptidase IV
13) Confidence 0.38 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.67 Pain Relevance 0.09
GLP-1 is degraded rapidly by the ubiquitous enzyme dipeptidyl-peptidase IV (DPP-4).
Positive_regulation (enzyme) of DPP-4
14) Confidence 0.38 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.67 Pain Relevance 0.09
GLP-1-receptor agonists (or GLP-1 mimetics) as injectable compoundsDipeptidyl-peptidase-IV (DPP-4) inhibitors (or incretin enhancers) as orally active substances
Positive_regulation (injectable) of DPP-4 associated with agonist
15) Confidence 0.38 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.59 Pain Relevance 0.16
In addition, CD26 is coexpressed with CXCR3 on the infiltrating Th1 lymphocytes and natural killer cells, and rapidly inactivates CXCL10 by NH2-terminal processing [22,44].
Positive_regulation (inactivates) of CD26 in natural killer cells
16) Confidence 0.37 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.45 Pain Relevance 0.65
Fibroblast-derived CD26/DPP IV is likely to be responsible for the observed NH2-terminal truncation since CD26 expression and DPP IV activity were detected on fibroblast membranes.
Positive_regulation (responsible) of CD26/DPP IV in Fibroblast
17) Confidence 0.35 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.28 Pain Relevance 0.14
To investigate whether DPP IV activity (or CD26 expression) could be upregulated in fibroblasts by cytokines under similar conditions to those used to induce CXCL10, cell cultures were stimulated with IL-1?
Positive_regulation (upregulated) of DPP IV in fibroblasts associated with cytokine
18) Confidence 0.35 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0 Pain Relevance 0.05
upregulated membrane-bound DPP IV activity on fibroblasts.
Positive_regulation (upregulated) of DPP IV in fibroblasts
19) Confidence 0.35 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.73 Pain Relevance 0.42
resulted in a modest but significant increase of membrane-associated DPP IV activity (Figure 10d).
Positive_regulation (increase) of DPP IV
20) Confidence 0.35 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.63 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox